Open AccessHitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies
Author(s) -
Kshitij Wagh,
Beatrice H. Hahn,
Bette Korber
Publication year - 2020
Publication title -
current opinion in hiv and aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.901
H-Index - 64
eISSN - 1746-6318
pISSN - 1746-630X
DOI - 10.1097/coh.0000000000000639
Subject(s) - glycan , immunogen , hiv vaccine , antibody , virology , glycoprotein , biology , neutralization , neutralizing antibody , human immunodeficiency virus (hiv) , computational biology , immunology , microbiology and biotechnology , monoclonal antibody , vaccine trial
The surface of the HIV-1 Env glycoprotein, the target of neutralizing antibodies, is extensively covered by N-linked glycans that create a glycan shield. Broadly neutralizing antibodies (bNAbs), the primary targets of HIV-1 vaccine design, have to negotiate this glycan shield. Here, we review the barriers and opportunities that the HIV-1 glycan shield presents for vaccine induction of bNAbs.